Activation of neutrophils and inhibition of the proinflammatory cytokine response by endogenous granulocyte colony-stimulating factor in murine pneumococcal pneumonia

Journal of Infectious Diseases

Volumn 189, Issue 8, 2004, Pages 1506-1514

  Knapp, Sylvia ^a   Hareng, Lars ^b   Rijneveld, Anita W ^a   Bresser, Paul ^a   Van Der Zee, Jaring S ^a   Florquin, Sandrine ^a   Hartung, Thomas ^b   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CD11B ANTIGEN; CHEMOATTRACTANT; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR ANTIBODY; INTERLEUKIN 1BETA; POLYCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CASE REPORT; CELL COUNT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; LEUKOCYTE ACTIVATION; LOBAR PNEUMONIA; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANIMALS; ANTIGENS, CD11B; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; COLONY COUNT, MICROBIAL; COMMUNITY-ACQUIRED INFECTIONS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG; MALE; MICE; MICE, INBRED BALB C; NEUTROPHIL ACTIVATION; NEUTROPHILS; PEROXIDASE; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 2142765327     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/382962     Document Type: Article

References (55)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10.
2. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340:207-14.
3. Bernstein JM. Treatment of community-acquired pneumonia - IDSA guidelines. Infectious Diseases Society of America. Chest 1999; 115(Suppl 3):9S-13S.
4. Campbell GD Jr, Silberman R. Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1998; 26:1188-95.
5. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-54.
6. Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144:312-8.
7. Campbell GD Jr. Commentary on the 1993 American Thoracic Society guidelines for the treatment of community-acquired pneumonia. Chest 1999; 115(Suppl 3):14S-8S.
8. Zhang P, Summer WR, Bagby GJ, Nelson S. Innate immunity and pulmonary host defense. Immunol Rev 2000; 173:39-51.
9. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 1992; 327:28-35.
10. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78:2791-808.
11. Tanaka H, Ishikawa K, Nishino M, Shimazu T, Yoshioka T. Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis. J Trauma 1996; 40:718-25; discussion 725-6.
12. Gross-Weege W, Dumon K, Dahmen A, Schneider EM, Roher HD. Granulocyte colony-stimulating factor (G-CSF) serum levels in surgical intensive care patients. Infection 1997; 25:213-6.
13. Kawakami M, Tsutsumi H, Kumakawa T, et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 1990; 76:1962-4.
14. Quinton LJ, Nelson S, Boe DM, et al. The granulocyte colony-stimulating factor response after intrapulmonary and systemic bacterial challenges. J Infect Dis 2002; 185:1476-82.
15. Tazi A, Nioche S, Chastre J, Smiejan JM, Hance AJ. Spontaneous release of granulocyte colony-stimulating factor (G-CSF) by alveolar macrophages in the course of bacterial pneumonia and sarcoidosis: endotoxin-dependent and endotoxin-independent G-CSF release by cells recovered by bronchoalveolar lavage. Am J Respir Cell Mol Biol 1991;4:140-7.
16. Zhang P, Bagby GJ, Kolls JK, et al. The effects of granulocyte colony-stimulating factor and neutrophil recruitment on the pulmonary chemokine response to intratracheal endotoxin. J Immunol 2001; 166:458-65.
17. Nelson S, Summer W, Bagby G, et al. Granulocyte colony-stimulating factor enhances pulmonary host defenses in normal and ethanol-treated rats. J Infect Dis 1991; 164:901-6.
18. Wang JM, Chen ZG, Colella S, et al. Chemotactic activity of recombinant human granulocyte colony-stimulating factor. Blood 1988; 72:1456-60.
19. Roilides E, Walsh TJ, Pizzo PA, Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991; 163:579-83.
20. Nathan CF. Respiratory burst in adherent human neutrophils: triggering by colony-stimulating factors CSF-GM and CSF-G. Blood 1989; 73:301-6.
21. Nelson S. Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Chest 2001; 119(Suppl 2):419S-25S.
22. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990; 141:471-501.
23. Goodman RB, Strieter RM, Martin DP, et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154:602-11.
24. Kalyanaraman M, Heidemann SM, Sarnaik AP. Macrophage inflammatory protein-2 predicts acute lung injury in endotoxemia. J Investig Med 1998; 46:275-8.
25. Hartung T. Anti-inflammatory effects of granulocyte colony-stimulating factor. Curr Opin Hematol 1998; 5:221-5.
26. Hartung T, Docke WD, Gantner F, et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995; 85:2482-9.
27. Weiss M, Gross-Weege W, Harms B, Schneider EM. Filgrastim (RHG-CSF) related modulation of the inflammatory response in patients at risk of sepsis or with sepsis. Cytokine 1996; 8:260-5.
28. Pajkrt D, Manten A, van der Poll T, et al. Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 1997; 90:1415-24.
29. Mielcarek M, Graf L, Johnson G, Torok-Storb B. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood 1998; 92:215-22.
30. Boneberg EM, Hareng L, Gantner F, Wendel A, Hartung T. Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-γ. Blood 2000; 95:270-6.
31. Boneberg EM, Hartung T. Granulocyte colony-stimulating factor attenuates LPS-stimulated IL-1β release via suppressed processing of proIL-1β, whereas TNF-α release is inhibited on the level of proTNF-α formation. Eur J Immunol 2002; 32:1717-25.
32. Weiss M, Moldawer LL, Schneider EM. Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Blood 1999; 93:425-39.
33. Lister PD, Gentry MJ, Preheim LC. Granulocyte colony-stimulating factor protects control rats but not ethanol-fed rats from fatal pneumococcal pneumonia. J Infect Dis 1993; 168:922-6.
34. Preheim LC, Snitily MU, Gentry MJ. Effects of granulocyte colony-stimulating factor in cirrhotic rats with pneumococcal pneumonia. J Infect Dis 1996; 174:225-8.
35. Hebert JC, O'Reilly M, Gamelli RL. Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg 1990; 125:1075-8.
36. Dallaire F, Ouellet N, Simard M, Bergeron Y, Bergeron MG. Efficacy of recombinant human granulocyte colony-stimulating factor in a murine model of pneumococcal pneumonia: effects of lung inflammation and timing of treatment. J Infect Dis 2001; 183:70-7.
37. Nelson S, Heyder AM, Stone J, et al. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis 2000; 182:970-3.
38. Root RK, Lodato RF, Patrick W, et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003; 31:367-73.
39. Rijneveld AW, Florquin S, Bresser P, et al. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003; 102:934-9.
40. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group. Eur Respir J 1989; 2:561-85.
41. Barsig J, Bundschuh DS, Hartung T, Bauhofer A, Sauer A, Wendel A. Control of fecal peritoneal infection in mice by colony-stimulating factors. J Infect Dis 1996; 174:790-9.
42. Knapp S, Leemans JC, Florquin S, et al. Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 2003; 167:171-9.
43. Rijneveld AW, Florquin S, Branger J, Speelman P, Van Deventer SJ, van der Poll T. TNF-α compensates for the impaired host defense of IL-1 type I receptor-deficient mice during pneumococcal pneumonia. J Immunol 2001; 167:5240-6.
44. Lichtman SN, Wang J, Hummel B, Lacey S, Sartor RB. A rat model of ileal pouch-rectal anastomosis. Inflamm Bowel Dis 1998; 4:187-95.
45. Leemans JC, Juffermans NP, Florquin S, et al. Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol 2001; 166:4604-11.
46. van der Poll T, Keogh CV, Buurman WA, Lowry SF. Passive immunization against tumor necrosis factor-α impairs host defense during pneumococcal pneumonia in mice. Am J Respir Crit Care Med 1997; 155:603-8.
47. Gorgen I, Hartung T, Leist M, et al. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-α. J Immunol 1992; 149:918-24.
48. Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84:1737-46.
49. Noursadeghi M, Bickerstaff MC, Herbert J, Moyes D, Cohen J, Pepys MB. Production of granulocyte colony-stimulating factor in the non-specific acute phase response enhances host resistance to bacterial infection. J Immunol 2002; 169:913-9.
50. + hematopoietic progenitor cells. Blood 1995; 86:4115-23.
51. Zhan Y, Lieschke GJ, Grail D, Dunn AR, Cheers C. Essential roles for granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF in the sustained hematopoietic response of Listeria monocytogenes-infected mice. Blood 1998; 91:863-9.
52. Zhan Y, Basu S, Lieschke GJ, Grail D, Dunn AR, Cheers C. Functional deficiencies of peritoneal cells from gene-targeted mice lacking G-CSF or GM-CSF. J Leukoc Biol 1999; 65:256-64.
53. Hebert JC, O'Reilly M, Yuenger K, Shatney L, Yoder DW, Barry B. Augmentation of alveolar macrophage phagocytic activity by granulocyte colony stimulating factor and interleukin-1: influence of splenectomy. J Trauma 1994; 37:909-12.
54. Ostergaard C, Benfield T, Gesser B, et al. Pretreatment with granulocyte colony-stimulating factor attenuates the inflammatory response but not the bacterial load in cerebrospinal fluid during experimental pneumococcal meningitis in rabbits. Infect Immun 1999; 67:3430-6.
55. Held TK, Mielke ME, Chedid M, et al. Granulocyte colony-stimulating factor worsens the outcome of experimental Klebsiella pneumoniae pneumonia through direct interaction with the bacteria. Blood 1998; 91:2525-35.